Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. by Pascual, A. et al.
M A J O R A R T I C L E
Challenging Recommended Oral and Intravenous
Voriconazole Doses for Improved Efﬁcacy
and Safety: Population Pharmacokinetics–Based
Analysis of Adult Patients With Invasive
Fungal Infections
Andres Pascual,1,a Chantal Csajka,2,4,a Thierry Buclin,2 Saskia Bolay,1 Jacques Bille,3 Thierry Calandra,1
and Oscar Marchetti1
1Infectious Diseases Service, 2Division of Clinical Pharmacology and Toxicology, Department of Medicine, and 3Institute of Microbiology, Centre
Hospitalier Universitaire Vaudois, University of Lausanne, and 4Department of Pharmaceutical Sciences, University of Geneva, Switzerland
(See the Editorial Commentary by Andes and Lepak, on pages 391–3.)
Background. Recommended oral voriconazole (VRC) doses are lower than intravenous doses. Because plasma
concentrations impact efﬁcacy and safety of therapy, optimizing individual drug exposure may improve these outcomes.
Methods. A population pharmacokinetic analysis (NONMEM) was performed on 505 plasma concentration mea-
surements involving 55 patients with invasive mycoses who received recommended VRC doses.
Results. A 1-compartment model with ﬁrst-order absorption and elimination best ﬁtted the data. VRC clearance
was 5.2 L/h, the volume of distribution was 92 L, the absorption rate constant was 1.1 hour−1, and oral bioavailability
was 0.63. Severe cholestasis decreased VRC elimination by 52%. A large interpatient variability was observed on clear-
ance (coefﬁcient of variation [CV], 40%) and bioavailability (CV 84%), and an interoccasion variability was observed on
bioavailability (CV, 93%). Lack of response to therapy occurred in 12 of 55 patients (22%), and grade 3 neurotoxicity
occurred in 5 of 55 patients (9%). A logistic multivariate regression analysis revealed an independent association
between VRC trough concentrations and probability of response or neurotoxicity by identifying a therapeutic range of
1.5 mg/L (>85% probability of response) to 4.5 mg/L (<15% probability of neurotoxicity). Population-based simulations
with the recommended 200 mg oral or 300 mg intravenous twice-daily regimens predicted probabilities of 49% and
87%, respectively, for achievement of 1.5 mg/L and of 8% and 37%, respectively, for achievement of 4.5 mg/L. With
300–400 mg twice-daily oral doses and 200–300 mg twice-daily intravenous doses, the predicted probabilities of achiev-
ing the lower target concentration were 68%–78% for the oral regimen and 70%–87% for the intravenous regimen, and
the predicted probabilities of achieving the upper target concentration were 19%–29% for the oral regimen and 18%–
37% for the intravenous regimen.
Conclusions. Higher oral than intravenous VRC doses, followed by individualized adjustments based on measured
plasma concentrations, improve achievement of the therapeutic target that maximizes the probability of therapeutic
response and minimizes the probability of neurotoxicity. These ﬁndings challenge dose recommendations for VRC.
Voriconazole (VRC) is a new-generation azole with
broad-spectrum antifungal activity [1]. Wide intraindi-
vidual/interindividual variability in VRC plasma con-
centrations was reported in healthy subjects [2]. Genetic
polymorphism of the CYP2C19 enzyme [3, 4] and non-
genetic factors (age, liver disease, and drug-drug inter-
actions) contributed to this variability [5]. VRC plasma
concentrations ranging from nonmeasurable values to
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15 mg/L were observed in patients with invasive fungal infec-
tions (IFIs) treated according to recommended dosing sched-
ules [5–10]. There is an increasing evidence of the association
between VRC exposure and response of infection or occurrence
of neurological and hepatic toxicity. These observations suggest
that therapeutic drug monitoring (TDM) may improve efﬁcacy
and safety of therapy in patients with life-threatening IFI. The
range of therapeutic concentrations and the doses required for
achieving this target need further investigations. Population
studies are a standard approach for characterizing the determi-
nants of drug pharmacokinetics/pharmacodynamics. We con-
ducted a population pharmacokinetic analysis in adult patients
receiving VRC for IFI (1) to describe factors inﬂuencing the
pharmacokinetic variability, (2) to assess associations between
plasma concentrations and efﬁcacy or neurotoxicity/hepatotox-
icity, and (3) to deﬁne intravenous and oral doses required
for achieving drug exposure with the most appropriate efﬁcacy-
toxicity proﬁle.
PATIENTS AND METHODS
Patients
All consecutive hospitalized patients receiving VRC therapy
on the advice of infectious diseases specialists over a
30-month period underwent TDM and were prospectively en-
rolled after providing written informed consent. VRC loading/
maintenance doses were based on package insert recommen-
dations and total body weight. The doses were adjusted (50%
increase/decrease) in case of nonresponse of IFI and toxicity
with trough plasma concentrations ≤1 and ≥5.5 mg/L, respec-
tively [5]. IFIs were classiﬁed according to deﬁnitions of the
European Organization for Research and Treatment of Cancer
and Mycoses Study Group (EORTC-MSG) [11]. The institu-
tional ethics committee approved the study.
VRC Plasma Concentrations
Days with measured VRC plasma concentrations were deﬁned
as study occasions, numbered from 1 to n (number of occa-
sions in each patient), with higher numbers reﬂecting later
time points during the study.
In 35 patients, measurements were performed 5 minutes
before and 2, 4, 6, and 12 hours after drug administration and
in 20 patients at the end of the dosing interval (Cmin). Three-
milliliter blood samples were collected in sodium-citrate tubes,
centrifuged within 2 hours, and frozen at −80°C. VRC plasma
concentrations were quantiﬁed by high-performance liquid
chromatography–ultraviolet (analytical range, 0.125–25 mg/L;
mean intrarun/interrun accuracy [± standard deviation {SD}],
93.7% ± 5.0%/96.5% ± 2.4%; and mean intrarun/interrun preci-
sion [± SD], 5.2% ± 1.5%/5.4% ± 0.9%) [12]. The method was
validated in an international quality control program [13].
Efﬁcacy and Safety of VRC Therapy
On each study occasion, data on VRC dose, route, comedica-
tions interacting with VRC metabolism, response of IFI, and
adverse events associated with VRC were collected. The response
of IFI was assessed by clinical, radiological, and microbiological
EORTC-MSG criteria [14]. National Cancer Institute (NCI) cri-
teria deﬁned type and severity of neurological/hepatic adverse
events and causal relationships with VRC [15].
Population Pharmacokinetics Analysis
This analysis was performed by NONMEM [16], using
mixed-effects regression to estimate population means/
variances of pharmacokinetic parameters and to identify
factors inﬂuencing them.
Structural Model
Search for the best model was performed by comparing
1- and 2-compartment models with ﬁrst-order oral absorption
and linear/saturable elimination after intravenous/oral admin-
istration. After estimation of VRC clearance (CL), volume of
distribution (V) and oral absorption rate constant (ka), the
absolute bioavailability (F) was estimated on the basis of
simultaneous ﬁt of intravenous and oral concentrations.
Absorption half-life, t½a, was calculated as ln(2)/ka, and elim-
ination half-life, t½z, was derived from ln(2)/(CL/V).
Statistical Model
Interindividual variations in VRC pharmacokinetics were de-
scribed using exponential error models with a mean of zero
and a variance of ω2. To account for ﬂuctuations in VRC
plasma concentrations at study occasions (ie, study days),
interoccasion variability (IOV) was tested on CL and F. A pro-
portional error model described residual variability with a
mean of zero and a variance of σ2.
Covariate Model
Inﬂuence and shape of the relationship between demographic
covariates and pharmacokinetic parameters were assessed by
visual inspection of plots of individual Bayesian estimates.
Inﬂuential covariates were sequentially tested using forward
selection followed by backward deletion steps: pharmacokinet-
ic parameters θ were modeled to depend linearly on the covar-
iates (eg, body weight centered on 70 kg; categorical covariates
coded as 0/1). Baseline covariates evaluated for model building
were sex, age, body weight, concomitant medications interact-
ing with VRC metabolism, and NCI grade 3 cholestasis (ie,
alkaline phosphatase [ALKP] and/or gamma glutamyl trans-
ferase [γ-GT] levels >20 times the upper limit of normal).
Parameter Estimation and Model Selection
Data were ﬁtted by a ﬁrst-order conditional method (FOCE
INTERACTION). Goodness-of-ﬁt statistics and graphical
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displays guided assessment of model choice and adequacy by
comparison of objective function values (approximate −2 max
log likelihood and χ2 distribution). A 5.9-point decrease in ob-
jective function for an additional parameter (2-sided P < .01)
determined a signiﬁcant difference between 2 models.
Model Validation
The bootstrap method with replacement was used to assess the
stability of the ﬁnal model (PsN-Toolkit, version 2.3.1) [17].
Two hundred data sets were reconstructed by resampling from
original data. Mean values and 95% conﬁdence intervals (CIs)
of bootstrap parameters were compared with estimates from
original data. In addition, a simulation based on ﬁnal pharma-
cokinetic estimates was performed with NONMEM in 1000
individuals to calculate 95% prediction intervals at each time
point.
VRC Plasma Concentration-Effect Relationships
Individual Bayesian estimates of log-transformed VRC peak
(Cmax), 12 hour-trough (Cmin), and area under the curve
(AUC0–12) were derived from the ﬁnal model. These variables,
VRC dose, route, and total body weight were explored for rela-
tionship with response and neurotoxicity/hepatotoxicity at
each study occasion. The occasion factor reﬂected a later time
point during the study and a longer duration of therapy. The
association of the above variables with response and neurotox-
icity/hepatotoxicity was analyzed by logistic regression for de-
riving the VRC plasma concentration range predicting the
most appropriate clinical efﬁcacy and safety proﬁle. Cholestasis
was coded either as dichotomous variable (cutoff of >20 times
the upper limit of normal ALKP and/or γ-GT levels [NCI
grade 3]) or by cutoffs >3 times (NCI grade 1), >5 times (grade
2) and >20 times (grade 3) the upper limit of normal. Statisti-
cal signiﬁcance was assigned at 2-sided P values of .05 (Stata
V10.0-2004, StataCorp, College Station, TX).
Model-Based Simulations for Optimizing VRC Doses
Concentration-time proﬁles at steady state in 1000 individuals
receiving oral and intravenous VRC doses of 200, 300, or 400 mg
twice daily and 200 mg 3 times daily were simulated by the ﬁnal
model including interpatient variability of CL, ka, and F. These
simulations aimed at predicting achievement of the therapeutic
VRC concentration target.
RESULTS
Patient Demographic and Dose Characteristics
Fifty-ﬁve white patients were studied (Table 1). According to-
package insert recommendations, the median initial mainte-
nance VRC dose was 295 mg (range, 200–400 mg) twice-daily
intravenously and 234 mg (range, 150–400 mg) twice-daily
Table 1. Demographic and Clinical Characteristics of the Study
Population
Demographic
Age, years 58 (23–78)
Sex
Male 39 (71)
Female 16 (29)
Total body weight, median kg (range) 68 (42–125)
Underlying condition
Hematological malignancy, neutropenia <0.5 G/L 35 (64)
Othera 16 (29)
None 7 (4)
IFI
Aspergillosisb,c 27 (49)
Candidiasisd 8 (14)
Othere 2 (4)
Possible pulmonary 12 (22)
Suspected (persistent neutropenic fever) 6 (11)
IFI response to antifungal therapy
Time to clinical assessment after starting VRC,
days, median (range)
11 (9–14)
Success 43 (78)
Complete response 33 (60)
Partial response 10 (18)
Lack of responsef,g 12 (22)
Persistence 3 (5)
Progression 9 (16)
Adverse events probably associated with VRC therapy
Time to clinical assessment after staring VRC, days,
median (range)
12 (4–30)
Neurotoxicity (encephalopathy/hallucinations), grade 3 5 (9)
Hepatic toxicity (cholestatic hepatopathy), grade 3h 7 (13)
Data are no. (%) of patients or median value (range).
Abbreviations: IFI, invasive fungal infection; VRC, voriconazole.
a Solid organ transplantation (n = 3), abdominal surgery (n = 3), chronic liver
disease (n = 3), chronic lung disease (n = 2), diabetes mellitus (n = 2), human
immunodeficiency virus infection (n = 2), and open knee fracture (n = 1).
b Proven aspergillosis (n = 19) and probable aspergillosis (n = 8).
c Pulmonary (n = 19), extrapulmonary (n = 8), sinusitis (n = 4: 1 with
intracerebral extension), disseminated infection (n = 3: 3 with involvement of
lung, 2 of sinus, 2 of liver, and 1 of skin), and intraabdominal infection (n = 1).
d Proven candidiasis (n = 4: 3 with fungemia, and 1 with osteomyelitis) and
probable candidiasis (n = 4, all hepatosplenic candidiasis).
e Proven osteomyelitis (1 due to Pseudallescheria boydii, 1 due to
Paecilomyces species).
f Proven sinus aspergillosis in 2 patients (1 with cerebral extension), proven
pulmonary aspergillosis in 1 patient, probable pulmonary aspergillosis in 3
patients, proven peritoneal aspergillosis in 1 patient, probable hepatosplenic
candidiasis in 2 patients, proven pulmonary zygomycosis in 1 patient, and
possible pulmonary IFI in 2 patients.
g In only 1 patient, the immune status and/or the underlying condition evolved
(ie, recovery from neutropenia) before response to VRC therapy could be
achieved, while in the remaining 11 cases no change occurred before clinical
response to antifungal therapy was observed (ie, 6 remained neutropenic, 2
continued to receive corticosteroids [with or without azathioprine], 1 had
AIDS, 1 had liver cirrhosis, and 1 had no underlying condition).
h Only grade 1 hepatic cytolysis was observed. Therefore, no specific
analysis of the association between VRC exposure and cytolytic toxicity was
performed (data not shown).
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orally; the median adjusted maintenance dose was 251 mg
(range, 150–450 mg) twice-daily intravenously and 235 mg
(range, 100–450 mg) twice-daily orally. Supplementary
Figures 1 and 2 show distributions of VRC doses and correla-
tions with plasma concentrations.
Pharmacokinetic Analysis
The pharmacokinetic analysis was based on 505 VRC plasma
concentration measurements (median, 8 per patient [range,
1–47]) on 197 study occasions (40 involving intravenous VRC
and 157 involving oral VRC; median, 3 occasions per patient
[range, 1–9 occasions]). The ﬁrst study occasion occurred at a
median of 5 days (range, 2–46 days) after the start of VRC
therapy; the median time between 2 consecutive occasions
was 7 days (range, 2–62 days) and from the ﬁrst to last occa-
sion was 28 days (range, 1–195 days; median, 7 days (range,
1–26 days) for intravenous VRC and 21 days [range, 1–189
days] for oral VRC). Sixteen patients received omeprazole
comedication.
Intravenous and oral VRC pharmacokinetics were best char-
acterized using a 1-compartment model on log-transformed
data with ﬁrst-order absorption; a 2-compartment model
could not be adapted. A nonlinear Michaelis-Menten elimina-
tion model did not describe data better than the linear model
(ΔOF = 0.0); the maximum metabolism rate (Vmax) and the
Michaelis-Menten constant (Km) were very large compared
to VRC concentrations, suggesting a linear increase of
VRC concentrations over the dosing range. Visual inspection
of individual plots of CL estimates and doses did not reveal
any trend toward decreased VRC elimination at higher doses.
VRC absolute bioavailability was estimated to be 63%; the
assignment of interindividual variability signiﬁcantly improved
the ﬁt (ΔOF =−63), whereas no variability on V and ka was
observed, probably owing to poor characterization of the
absorption phase. Because of variations of VRC concentra-
tions, interoccasion variability was tested on CL and F. The
best ﬁt was obtained when F was allowed to vary, suggesting
signiﬁcant interdose variability in VRC oral bioavailability
(ΔOF = −137). Among covariates showing a potential inﬂu-
ence on VRC pharmacokinetics, a signiﬁcant decrease in
CL (−52%) was observed in patients with grade 3 cholestasis
(ΔOF = −45). Omeprazole inhibited VRC CL by 20% but did
not reach statistical signiﬁcance (ΔOF = −2.6), and no inﬂu-
ence on ka was observed (ΔOF =−0.3). The impact of sex,
body weight, or age was nonsigniﬁcant (ΔOF <−1.1). Parame-
ter estimates for the ﬁnal models with and without interocca-
sion variability on F are summarized in Table 2. The average
VRC absorption half-life (t½a) was 0.63 hours, and the average
elimination half-life (t½z) was 12 hours, which doubled in
grade 3 cholestasis. Concentration-time proﬁles for oral and
intravenous VRC with average population prediction and 90%
intervals are presented in Figure 1, and goodness of ﬁt plots
are presented in Supplementary Figure 3.
Model Validation
Median values and 95% CIs of parameter bootstrap estimates
are presented in Table 2. Pharmacokinetic parameters of the
ﬁnal population models from original data (with and without
interoccasion variability of F) were close to median bootstrap
values and all were included in their 2.5–97.5 percentiles, indi-
cating that the ﬁnal models are accurate.
Plasma Concentration-Effect Relationships
Infection did not responding to VRC therapy in 12 patients
(Table 1) on 16 study occasions: 4 during intravenous therapy
(2 on the ﬁrst occasion, 1 on the second, and 1 on the
seventh) and 12 during oral therapy (11 on the ﬁrst and
second occasions and 1 on the fourth occasion). NCI grade 3
neurotoxicity (encephalopathy with agitation, confusion,
hallucinations, and myoclonies) probably caused by VRC
occurred in 5 patients (Table 1) on 12 study occasions
(8 during intravenous therapy and 4 during oral therapy [5 on
the ﬁrst occasion, 4 on the second, and 3 on or beyond the
third]). Seven patients (Table 1) presented grade 3 cholestasis
on 18 occasions during oral VRC (2 on the ﬁrst occasion,
5 on the second, and 11 on or beyond the third). Nine patients
without baseline cholestasis developed grade 1 (n = 6), grade 2
(n = 2), or grade 3 (n = 1) cholestasis during VRC therapy;
worsening of baseline cholestasis occurred in 7 of 23 patients
with grade 1 (6 progressed to grade 2, and 1 progressed to
grade 3) and in 2 of 10 patients with grade 2 (both progressed
to grade 3); in 2, baseline grade 3 remained unchanged.
No independent association of VRC dose, intravenous/oral
route, or body weight with efﬁcacy and safety was found in
the logistic multivariate regression model (data not shown).
The results of the logistic multivariate regression analysis of
VRC exposure and response or neurotoxicity are summarized
in Supplementary Table 1. A signiﬁcant association between
log-transformed Cmax, Cmin, or AUC0–12 and response was ob-
served for oral (P < .001), while no association for intravenous
VRC was found. The time factor (study occasion), reﬂecting
duration of therapy, added to VRC exposure improved this
association (P < .005).
Grade 3 neurotoxicity was signiﬁcantly associated with
Cmax, Cmin, or AUC0–12 for both oral and intravenous VRC
(P < .01), without additional inﬂuence of the time factor
(study occasion).
No association was observed between Cmax, Cmin, or AUC0–12
and grade 3 cholestasis (P = .3). An ordered logistic regression
suggested a possible association between Cmin and any cholestasis
(grade 1–3; P = .01), which was not improved by the occasion
factor.
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VRC trough (Cmin) plasma concentration, a parameter easily
measurable in routine clinical practice, was selected for logistic
regression models predicting probabilities of response of IFI
and grade 3 neurotoxicity over the measured concentrations
range (Figure 2A and 2B). VRC troughs of 1.5 and 4.5 mg/L
were associated with an 85% probability of response and a
15% probability of grade 3 neurotoxicity, respectively.
Model-Based Simulations for Optimizing VRC Doses
Model-based simulations of concentrations proﬁles after intra-
venous and oral VRC were derived while assigning interpati-
ent variability to oral CL and F and pooling interoccasion and
intrapatient variability. Table 3 reports predicted steady-state
trough concentrations for 200, 300, or 400 mg twice-daily and
200 mg 3 times daily intravenous or oral VRC. Predicted per-
centages of patients with VRC concentrations <1.5 mg/L
(<85% probability of response) and >4.5 mg/L (>15% proba-
bility of neurotoxicity) with different intravenous and oral reg-
imens are shown. Figure 3A–D simulates steady-state VRC
concentrations proﬁles for intravenous and oral regimens best
achieving predicted therapeutic targets.
DISCUSSION
This analysis characterized the VRC population pharmacoki-
netics during prolonged therapy with recommended
Table 2. Population Pharmacokinetic Estimates of Voriconazole
Population Meana Bootstrap Evaluationb
Parameter Estimate 95% CIc Mean 95% CIc
A. Final model assuming no interoccasion variability on F
Structural model
CL (L/h) 5.5 3.8–7.1 5.7 4.2–7.5
V (L) 101 61–141 95 47–140
ka (h−1) 1.1 .7–1.4 0.8 0.2–1.4
F 0.63 .22–.91 0.68 .45–.95
θrifampicin
d 3.1 2.3–3.8 3.1 2.2–3.7
θcholestasis
e −0.55 −.36 –−.75 −0.55 −.18 –−.69
Statistical modelf CVg CVg
ωCL (%) 42 53 42 51
ωF (%) 95
h 78 116 67
σ (%) 70 33 71 25
B. Final model integrating the interoccasion variability on F 95% CIc 95% CIc
Structural model
CL (L/h) 5.2 4.0–6.3 5.3 4.0–6.4
V (L) 92 63–120 83.6 43–116
ka (h−1) 1.1 .6–1.6 0.8 .1–1.6
F 0.63 .30–.87 0.65 .48–.82
θrifampicin
d 3.0 2.4–3.6 3.0 1.9–3.7
θcholestasis
e −0.52 −.42 –−.62 −0.51 −.22 –−.65
Statistical modelf CVg CVg
ωCL (%) 40 50 41 51
ωF (%) 84
h 68 98 77
IOV on F (%) 93g 52 84 63
σ (%) 59 34 64 41
Abbreviations: CI, confidence interval; CL, clearance; F, oral bioavailability; IOV, interoccasion variability; ka, absorption rate constant; V, volume of distribution.
a Estimate from the original data set.
b Statistics by 200 bootstrap analyses.
c Data are around the mean estimate. For F, the antilogit of the 95% CI derived from the logit function is reported.
d Relative increase in CL in presence of rifampicin coadministration.
e Relative decrease in CL in case of severe hepatic cholestasis.
f ω is an estimate of interindividual variability, and σ is an estimate of residual variability in the plasma concentrations, expressed as coefficient of variation.
g Coefficient of variation (CV), calculated as
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
standard errorestimate=estimate
p
expressed as a percentage.
h Estimates of variability on F within the logit function.
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intravenous and oral doses in adult patients with IFI. A valida-
tion by bootstrap estimates conﬁrmed the accuracy and stabi-
lity of a 1-compartment model with ﬁrst-order absorption and
linear elimination. Oral bioavailability and severe cholestatic
hepatopathy were major determinants of variability of VRC
plasma concentrations, whereas VRC dosing, body weight,
and demographic characteristics had no signiﬁcant effect. The
logistic regression analysis revealed a signiﬁcant association
between VRC exposure and probability of response to therapy
or severe neurotoxicity. The VRC trough plasma concentra-
tion range of 1.5 to 4.5 mg/L was identiﬁed as the therapeutic
target with a clinically appropriate efﬁcacy-safety proﬁle
(>85% probability of response and <15% probability of neuro-
toxicity), close to that recently reported by Troke et al [18].
Reassessment of oral and intravenous doses by model-based
simulations challenged the package insert recommendations
by identifying revised regimens best predicting achievement of
the therapeutic target.
Age, sex, and body weight were not found to affect signiﬁ-
cantly VRC pharmacokinetics. Some parameters of this VRC
population pharmacokinetic analysis in patients with IFI dif-
fered from those in previous reports [2, 19]. The estimated
VRC oral bioavailability was lower (60%) than previously
observed (80%–95%) [20, 21]. As vomiting, mucositis, and
Figure 1. A, Voriconazole steady-state plasma concentrations normalized for a 200-mg oral dose (open circles; n = 173) and after a 400-mg oral
loading dose (black circles; n = 23). B, Voriconazole steady-state plasma concentrations (open circles; n = 126) normalized for a 200-mg intravenous dose
(1.5-hour infusion). The solid line represents the population prediction, and the dashed lines the 90% prediction interval.
Figure 2. A, Logistic regression model predicting the probability of response to voriconazole (VRC) therapy (solid line) and of grade 3 neurotoxicity
probably associated with VRC therapy (dashed line) as a function of the VRC trough plasma concentration. The vertical dotted lines indicate the
identiﬁed 1.5–4.5 mg/L therapeutic range. B, VRC trough plasma concentrations and probabilities predicted by the logistic regression models for (1)
response of infection to VRC therapy and (2) grade 3 neurotoxicity associated with VRC. The VRC trough plasma concentration range associated with a
>85% probability of response to therapy and a <15% probability of neurotoxicity related to therapy is highlighted in gray and bold.
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Figure 3. Model-based simulations of voriconazole (VRC) steady-state pharmacokinetic proﬁles (with 10, 25, 50, 75, and 90 percentiles) after the
following VRC dosing regimens: 300 mg twice-daily intravenously (A), 200 mg twice-daily intravenously (B ), 300 mg twice-daily orally (C ), 400 mg
twice-daily orally (D ). The shaded zones represent the proposed therapeutic interval for VRC trough plasma concentrations of 1.5–4.5 mg/L.
Table 3. Probability of Achieving Different Voriconazole Trough Plasma Concentrations Targets With 200, 300, and 400 mg Twice-
Daily Oral and Intravenous Dosing Regimens
Probability, by Dosing Regimen and Route of Administration
200 mg Twice Daily 300 mg Twice Daily 400 mg Twice Daily
VRC Trough Concentration Target (mg/L) Oral (%) Intravenous (%) Oral (%) Intravenous (%) Oral (%) Intravenous (%)
1 60 86 78 95 95 97
1.5a 49 70 68 87 78 92
2 35 56 55 77 67 86
4 11 22 22 43 35 56
4.5a 8 18 19 37 29 50
5 4.5 15 16 26 26 44
The percentages represent the probabilities of obtaining trough concentrations above the reported targets. The dosing regimens with the most appropriate
predicted probabilities of reaching the therapeutic concentration range (ie maximizing efficacy by minimizing neurotoxicity) are reported in bold and underlined.
Similar probability of treatment outcome can be obtained with the 200 mg 3-times daily oral and intravenous regimens (69% and 86% of patients would reach
the 1.5 mg/L lower concentration target and 20% and 37% of patients would have concentrations exceeding the 4.5 mg/L upper target, after oral and
intravenous administration, respectively). These results are very close to those reported in the table with the 300 mg twice-daily oral and intravenous dosing
regimens.
Abbreviation: VRC, voriconazole.
a The therapeutic target concentrations for efficacy (ie >85% probability of response) and safety (ie <15% probability of grade 3 neurotoxicity).
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diarrhea are frequent in hemato-oncological patients, gastroin-
testinal function may have inﬂuenced VRC absorption. This
may explain the large interindividual and interoccasion vari-
ability in oral bioavailability, as reported in allogeneic hemato-
poietic stem cell transplantation [22]. Aspects inﬂuencing
drug absorption were, however, not systematically investigated
in the present study.
The estimated VRC 12-hour half-life is consistent with
reports over the dosing range 200–400 mg, while the expected
dose-dependent saturable elimination was not observed. Con-
ﬂicting results have been reported on nonlinearity of the rela-
tionship between VRC dosing and elimination in children and
adults [2, 23–25]. The linearity in the present study may result
from the limited and unbalanced numbers of measurements
across doses, with lacking quantiﬁcation of the biexponential
disposition and nonlinear components. The large interocca-
sion variability in oral VRC bioavailability with low concentra-
tions in few patients receiving high doses might have
precluded the estimation of a saturable elimination process.
The lack of effect of body weight on VRC clearance does
not support body weight–adjusted dosing. As in previous in-
vestigations [26], severe cholestasis markedly decreased VRC
clearance, which requires initial dose adjustment followed by
close monitoring of liver parameters and plasma concentra-
tions. As VRC is metabolized by CYP2C9, CYP2C19, and
CYP3A4, drug interactions are expected with inhibitors or in-
ducers of these enzymes. Omeprazole induced a nonsigniﬁcant
20% decrease in VRC clearance, which is lower than the 40%
decrease reported by Wood et al [27]. The smaller than expect-
ed effect might be due to substantially larger inﬂuences of
other factors on variability of exposure. CYP2C19 genetic poly-
morphism [4, 28, 29] may have contributed to interpatient var-
iability. However, no genotyping data were available, a
limitation of the present study.
This population analysis revealed a signiﬁcant association
between VRC trough concentrations >1.5 mg/L and therapeu-
tic effect (>85% probability of response). This threshold was
consistent with recently reported minimum inhibitory concen-
tration required to inhibit the growth of 90% of organisms
and epidemiological cutoffs of most VRC-susceptible fungal
species, as well as clinical reports [18, 30–33]. This association
was not observed for intravenous VRC, suggesting that,
beyond the small number of events during short intravenous
courses, intraindividual/interindividual variability in oral VRC
bioavailability is a major determinant of infratherapeutic con-
centrations resulting in nonresponse. The association of re-
sponse with the time factor is consistent with adjustment of
VRC doses in nonresponding patients and with duration of
therapy. The limited data set does not allow the assessment
of other factors that may contribute to clinical improvement
over time, such as recovery of the immune status or evolving
underlying conditions. No information on whether VRC con-
centrations need to be adjusted according to the site of infec-
tion is available.
On the side of toxicity, an association between VRC
trough concentrations >4.5 mg/L and severe neurological
adverse events (>15% probability) was found, while the
time factor had no impact as these occurred early during
therapy. A possible association of VRC concentrations with
cholestasis was observed. Gorski et al reported the occur-
rence of cholestasis according to VRC dose and duration of
therapy [34]. The present data suggest that cholestasis may
reﬂect both a cause and consequence of increased VRC ex-
posure; a possible vicious circle between cholestasis and
VRC accumulation deserves conﬁrmation in independent
samples. No clinically signiﬁcant hepatic cytolysis occurred
during VRC therapy.
Model-based simulations involving patients with normal
hepatic function predicted that recommended VRC doses of
300 mg intravenously and 200 mg orally twice daily would
achieve the 1.5 mg/L threshold with probabilities of 87% and
49%, respectively, and the 4.5 mg/L threshold with probabili-
ties of 37% and 8%, respectively. A narrower concentrations
target of 2–4 mg/L with a marginal outcome improvement
(>85%–90% probability of response and < 10%–15% probabili-
ty of neurotoxicity) would signiﬁcantly increase the trough
outliers. Recommended doses are challenged by neurotoxicity
for intravenous therapy and nonresponse for oral therapy. In
acute infection, efﬁcacy has the priority: 300 mg intravenously
and 400 mg orally twice daily rapidly achieve VRC concentra-
tions >1.5 mg/L, while being associated with a higher risk of
neurotoxicity. In responding infection or prophylaxis, safety
prevails on rapid achievement of therapeutic concentrations:
200 mg intravenously and 300 mg orally twice daily are associ-
ated with a lower risk of neurotoxicity. The 60% oral bioavail-
ability observed in this population may explain the differences
in the required intravenous/oral VRC doses.
In both scenarios, despite adjusted initial doses, achieve-
ment of therapeutic concentration targets remains suboptimal
because of important intrapatient/interpatient variability. Indi-
vidualized adjustments based on VRC trough concentrations
during the ﬁrst week of therapy may avoid prolonged infra-
therapeutic or supratherapeutic VRC exposure by minimizing
risks of decreased efﬁcacy or neurotoxicity. Further monitor-
ing of plasma concentrations may be necessary after a change
of dose or route, lack of response, or suspected neurotoxicity.
VRC therapy guided by monitoring trough concentrations is
recommended by many experts as a component of optimal
patient care [5, 22, 35–38]. A Bayesian feedback strategy would
be ideally suited for extrapolation of troughs from concentra-
tions measured at any time during the dosing interval [39]. As
real-time CYP2C19 genotyping is not routinely available, the
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clinical role of this research tool for optimizing VRC exposure
remains to be deﬁned.
In conclusion, this analysis involving adult patients with IFI
challenges recommended VRC doses. Initial 300–400 mg oral
and 200–300 mg intravenous twice-daily doses are best suited
to achieve the therapeutic concentration of 1.5–4.5 mg/L.
Given the multiple factors contributing to variable VRC ab-
sorption, disposition, and clearance, TDM is needed for
rapidly identifying inappropriate exposure and optimizing efﬁ-
cacy and safety on an individual basis.
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